Analyst Price Targets — TXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 12:45 pm | — | Leerink Partners | $40.00 | $44.12 | TheFly | 10x Genomics price target raised to $40 from $23 at Leerink |
| July 14, 2026 10:55 am | Kyle Mikson | Canaccord Genuity | $50.00 | $41.77 | TheFly | 10x Genomics price target raised to $50 from $32 at Canaccord |
| July 9, 2026 10:56 am | Kallum Titchmarsh | Morgan Stanley | $37.00 | $37.47 | TheFly | 10x Genomics price target raised to $37 from $22 at Morgan Stanley |
| June 24, 2026 8:49 am | Luke Sergott | Barclays | $40.00 | $31.87 | TheFly | 10x Genomics price target raised to $40 from $30 at Barclays |
| May 12, 2026 12:26 pm | — | Morgan Stanley | $22.00 | $20.60 | TheFly | 10x Genomics price target raised to $22 from $20 at Morgan Stanley |
| April 14, 2026 10:41 am | — | Barclays | $30.00 | $23.58 | TheFly | 10x Genomics price target raised to $30 from $22 at Barclays |
| March 2, 2026 1:18 pm | Daniel Arias | Stifel Nicolaus | $25.00 | $22.38 | StreetInsider | 10X Genomics (TXG) PT Raised to $25 at Stifel on Solid New Product Adoption |
| February 20, 2026 11:39 am | — | UBS | $20.00 | $19.19 | TheFly | 10x Genomics price target raised to $20 from $14 at UBS |
| February 13, 2026 1:36 pm | — | Deutsche Bank | $17.00 | $19.40 | TheFly | 10x Genomics price target raised to $17 from $16 at Deutsche Bank |
| February 13, 2026 12:08 pm | — | Stifel Nicolaus | $20.00 | $17.51 | TheFly | 10x Genomics price target raised to $20 from $15 at Stifel |
Latest News for TXG
Mitesco (OTCMKTS:MITI - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Mitesco and 10x Genomics' net
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026.
TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew…
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TXG.
U.S. House Trading
No House trades found for TXG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.